Astra S DR MRI IPG, Astra S SR MRI IPG, Astra XT SR MRI IPG, Azure S DR MRI IPG, Azure S SR MRI IPG, Azure XT DR MRI IPG
Medtronic, Inc. · Decision date Oct 5, 2026
What did the FDA decide?
FDA records P980035/S847 as a supplement to PMA P980035, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 5, 2026.
FDA approval order statement
process and equipment updates of the manufacturing process of MR Delta 26H3 batteries used in Medtronic CRM devices
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 5, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P980035/S847
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- NVZ
- Decision code
- OK30
- Decision date
- Oct 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pulse generator, permanent, implantable.
- Applicant
- Medtronic, Inc.
- Product code
- NVZ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P980035. Subsequent supplements may change the device or its indications.
FDA decision timeline
P980035 · Original PMA
MEDTRONIC KAPPA 700/600 SERIES PULSE GENERATORS AND MODEL 9953 SOFTWARE
P980035/S847 received
Application receipt date recorded by FDA.
P980035/S847 · FDA decision
30-Day Notice
P980035/S848 · Related supplement
Astra S DR MRI IPG (X3DR01); Astra S SR MRI IPG (X3SR01); Astra XT DR MRI IPG (X1DR01); Astra XT SR MRI IPG (X1SR01); Az
P980035/S849 · Related supplement
Astra S DR MRI IPG; Astra S SR MRI IPG; Astra XT DR MRI IPG; Astra XT SR MRI IPG; Azure S DR MRI IPG; Azure S SR MRI IPG
Timeline entries are records held by MedtechLedger for P980035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P980035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Jan 29, 1999 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P980035/S847
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

